Ciulla Thomas's Insider Trades & SAST Disclosures
Ciulla Thomas's most recent trade in Viridian Therapeutics Inc was a trade of 50,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 5, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Ciulla Thomas.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Ciulla Thomas | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.62 per share. | 10 Jan 2023 | 2,170 | 305,590 (0%) | 0% | 1.6 | 3,515 | Common Stock |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 187,500 | 187,500 | - | - | Employee Stock Option (right to buy) | |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 1.25 per share. | 04 Jan 2023 | 5,000 | 302,760 (0%) | 0% | 1.3 | 6,250 | Common Stock |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.95 per share. | 04 Jan 2023 | 5,000 | 307,760 (0%) | 0% | 1.0 | 4,750 | Common Stock |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 138,750 | 138,750 | - | - | Stock Option (Right to Buy) | |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 46,250 | 301,810 (0%) | 0% | 0 | Common Stock | |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.40 per share. | 21 Sep 2021 | 2,560 | 255,560 (0%) | 0% | 6.4 | 16,384 | Common Stock |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2021 | 209,375 | 209,375 | - | - | Stock Option (Right to Buy) | |
| Clearside Biomedical Inc | Thomas Ciulla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2021 | 103,125 | 253,122 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges